
Paradox Immunotherapeutics Gains $10 Million Investment from SymBiosis to Propel Treatments for Protein Misfolding Disorders
On February 25, 2025, Paradox Immunotherapeutics, a Toronto-based pharmaceutical company dedicated to developing innovative antibody therapies for protein misfolding diseases,…